

Implementation of CKD-EPI for calculation of eGFR at S.V.U.H.

Janice Reeve PhD., FRCPath

Principal Clinical Biochemist



Glomerular Filtration Rate

- Just one of the kidneys functions - decreased GFR sign of kidney disease
- Measured using plasma clearance of exogenous markers
- Estimates (eGFR) based on:
 - Endogenous filtration markers
 - Variables associated with non-GFR determinants of concentration
- eGFR more sensitive and accurate than filtration marker concentration alone
- Inaccuracies between eGFR and GFR
 - Inaccuracies in endogenous filtration marker assays
 - Differences in development datasets vs 'real-life'
- Imprecision in estimates
 - Random variation in surrogates of non-GFR determinants

Modification of Diet and Renal Disease Study eGFR

- Relationship between creatinine and GFR non-linear
- Multicentre, controlled trial; evaluated the effect of dietary protein restriction & BP control renal disease progression
- Formula based on 1,628 CKD patients
 - GFR <60 mL/min/1.73m² (¹²⁵I-iothalamate clearance)
 - 4 variable equation; age (≥18 years), gender, ethnicity, serum creatinine conc.
 - Modified - differences in creatinine methods
- At SVUH, Roche creatinine enzymatic assay standardised to ID-MS

$$175 \times (\text{SCr } \mu\text{mol/L} \times 0.011312)^{-1.154} \times (\text{Age})^{-0.203} \times 0.742 \text{ (if female)} \left[\times 1.212 \text{ (if black)} \right]$$

Chronic Kidney Disease Epidemiology Collaboration eGFR formula

- To be as accurate as MDRD at low GFR AND more accurate at higher GFR
- Applies different coefficients to the same 4 MDRD variables
- Developed using 8,254 subjects
 - Wide range of kidney function
 - High number of black participants (32% vs 12% MDRD)
 - GFR measured using ^{125}I -iothalamate clearance
 - Serum creatinine traceable to ID-MS
- Does not overcome the limitations inherent to creatinine based eGFR

CKD-EPI gender based serum creatinine equations for eGFR

Gender	Serum [creatinine]	>18 years
Male	≤80 μmol/L	$141 \times (\text{SCr}/80)^{-0.411} \times (0.993)^{\text{Age}}$
	>80 μmol/L	$141 \times (\text{SCr}/80)^{-1.209} \times (0.993)^{\text{Age}}$
Female	≤62 μmol/L	$144 \times (\text{SCr}/62)^{-0.329} \times (0.993)^{\text{Age}}$
	>62 μmol/L	$144 \times (\text{SCr}/62)^{-1.209} \times (0.993)^{\text{Age}}$

[x 1.159, **if black**]

Kidney Disease Improving Global Outcomes GFR and ACR categories

CKD diagnosed over 3 months

				Persistent albuminuria categories		
				Description and range		
				A1	A2	A3
				Normal to mildly increased	Moderately increased	Severely increased
				<30 mg/g <3 mg/mmol	30-300 mg/g 3-30 mg/mmol	>300 mg/g >30 mg/mmol
GFR categories (ml/min/ 1.73 m ²) Description and range	G1	Normal or high	≥90	No CKD without markers of kidney damage	Yellow	Orange
	G2	Mildly decreased	60-89		Yellow	Orange
	G3a	Mildly to moderately decreased	45-59	Yellow	Orange	Red
	G3b	Moderately to severely decreased	30-44	Orange	Red	Red
	G4	Severely decreased	15-29	Red	Red	Red
	G5	Kidney failure	<15	Red	Red	Red

Green: low risk (if no other markers of kidney disease, no CKD); Yellow: moderately increased risk; Orange: high risk; Red, very high risk.

Increasing risk →

↑ Increasing risk

CKD-EPI versus MDRD eGFR: validation dataset

Variable and Equation	All Patients	Patients with estimated GFR <60 ml/min/1.73 m ²	Patients with estimated GFR ≥60 ml/min/1.73 m ²
Median difference (95% CI), mL/min per 1.73 m²[†]			
CKD-EPI	2.5 (2.1 - 2.9)	2.1 (1.7 - 2.4)	3.5 (2.6 - 4.5)
MDRD Study	5.5 (5.0 - 5.9)	3.4 (2.9 - 4.0)	10.6 (9.8 - 11.3)
Interquartile range for differences (95% CI) - mL/min per 1.73 m²[‡]			
CKD-EPI	16.6 (15.9 - 17.3)	11.3 (10.7 - 12.1)	24.2 (22.8 - 25.3)
MDRD Study	18.3 (17.4 - 19.3)	12.9 (12.0 - 13.6)	25.7 (24.4 - 27.1)
P₃₀ (95% CI) - %[§]			
CKD-EPI	84.1 (83.0 - 85.3)	79.9 (78.1 - 81.7)	88.3 (86.9 - 89.7)
MDRD Study	80.6 (79.5 - 82.0)	77.2 (75.5 - 79.0)	84.7 (83.0 - 86.3)

CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; GFR = glomerular filtration rate; MDRD = Modification of Diet in Renal Disease.

* To convert GFR from mL/min per 1.73 m² to mL/s per 1.73 m², multiply by 0.0167.

[†] Median difference refers to measured GFR minus estimated GFR.

[‡] Interquartile range refers to the 25–75th percentile.

[§] P₃₀ refers to percentage of GFR estimates that are within 30% of measured GFR.

Comparison of eGFR by MDRD versus CKD-EPI

- **Better accuracy:** classification of GFR stage correct more often than classification by MDRD
 - 63% vs 34%, $p < 0.001$
- **Reduced CKD prevalence:** produces higher eGFRs at values $>30 \text{ mL/min/1.73m}^2$ vs MDRD
 - Lower CKD prevalence; 11.5 vs 13.1 %
 - Reclassification more evident in <65 years, females and non-blacks
 - Better eGFR and fewer co-morbidities means reclassification = better outcomes
- **CKD prevalence still high in elderly**
- **More targeted healthcare resources**

CKD-EPI eGFR and the guidelines

- Serum creatinine and eGFR to be reported
- **KDIGO Clinical Practice Guideline (2012)**
 - Report eGFR in adults using the 2009 CKD-EPI creatinine equation
 - An alternative is acceptable if it demonstrates improved accuracy to this equation
- **NICE CKD in adults: assessment and management Clinical Guideline 182 (2014)**
 - CKD-EPI eGFR based on serum creatinine
 - Calibration traceable to SRM; zero bias to ID-MS
- **ACB statement (2016)** supports the NICE recommendations
 - Suggests an implementation date of no later than April 2017

Setting up CKD-EPI on APEX: Step 1

Derivation of an exponential figure (EEPI) by rule

Gender

Serum [creatinine]

Male

≤80 μmol/L

$$141 \times (\text{SCr}/80)^{0.411} \times (0.993)^{\text{Age}}$$

>80 μmol/L

$$141 \times (\text{SCr}/80)^{-1.209} \times (0.993)^{\text{Age}}$$

Female

≤62 μmol/L

$$144 \times (\text{SCr}/62)^{0.329} \times (0.993)^{\text{Age}}$$

>62 μmol/L

$$144 \times (\text{SCr}/62)^{-1.209} \times (0.993)^{\text{Age}}$$

Setting up CKD-EPI on APEX: Step 2

Gender specific eGFR using the derived exponential

```
If NAGE GT 18 AND SEX EQ M
Formula (a) :
141*((A/79.56)**B)*(0.993**NAGE)
To enter another set of Conditions/Formulae use F12 on Formula field
```

3	Test	3	Low	3	High	3	Error	3	3	Test	3	Low	3	High	3	Error	3	
3A	CRE	3		3		3		3	3G			3		3		3		3
3B	EEPI	3		3		3		3	3H			3		3		3		3

OR

```
3If NAGE GT 18 AND SEX EQ F 3
3- then use Formula (b) : 3
3144*((A/61.88)**B)*(0.993**NAGE) 3
3or - either use Formula (c) - if one or both conditions fail (default) 3
3 3
3 - or Condition Failure Comment : NEGFR 3
```




Description : Patient gender not specified. Unable to calculate EGFR

'Dual reporting' of MDRD eGFR and (suppressed) CKD-EPI eGFR

<p>123456 DUMMY, JOHN M MR 03/12/1969 PATHR Elm Park Dublin 4 Pathology Reports 07/07/2017 09:37 S Specimen No : BB871574Q Biochemistry <PgUp> for earlier</p>	<p>07/07/2017 09:37 123456 ROCHE, WENDY F MS 26/03/1979 PATHR 4 OUR LADY'S CLOSE Pathology Reports 07/07/2017 09:38 S Specimen No : BB871576H Biochemistry <PdUp> for earlier</p>
<p>CKD-EPI eGFR Estimated GFR Comments : EGFR result</p>	<p>123456 DUMMY, M M 01/05/2005 PATHR SVUH Pathology Reports 07/07/2017 09:38 S Specimen No : BB871577Y Biochemistry <PgUp> for earlier</p>
<p>07/07/2017 09:38 Serum</p>	<p>07/07/2017 09:38 Serum</p>
<p>Creatinine Exponent EPI-eGFR Auth CKD-EPI eGFR Estimated GFR</p>	<p> Creatinine 56 umol/L (59 to 104) Auth Exponent EPI-eGFR ^-0.411 Auth CKD-EPI eGFR ^eGFR is not available for those <18 years of age. Auth Estimated GFR eGFR is not available for those <18 years of age. Auth </p>

eGFR and CKD stage by MDRD and CKD-EPI equations




- Random 2 weeks examined
- n = 17,055
- MDRD and CKD-EPI paired eGFR
- Classified to CKD stage 1-5 despite once off measure
- eGFR over 90 reported as >90 mL/min/1.73m²

Reclassification of eGFR stage: CKD-EPI vs MDRD eGFR

- 'Reclassification' - if CKD stage changed with CKD-EPI eGFR
- 14,150 (**83%**) patients remained in the same CKD stage
- 2,905 (**17%**) patients were reclassified
 - 13.6% had a better eGFR
 - 3.4% had a worse eGFR

	Number (%)	Reclassified by CKD-EPI; Number (%)
All	17,055	2,905 (17%)
<65 years	9,210 (54%)	2,134 (23.2%) ←
≥65 years	7,845 (46%)	771 (9.8%)
Male	8,127	1,200 (14.7%)
<65 years	4,279 (52.7%)	827 (19.3%)
≥65 years	3,848 (47.3%)	373 (9.7%)
Female	8,928	1,705 (19.1%) ←
<65 years	4,931 (55.2%)	1,307 (26.5%) ←
≥65 years	3,997 (44.8%)	398 (10%)

Reclassification of eGFR stage: CKD-EPI vs MDRD eGFR



CKD stages 1&2
need information
on albuminuria

CKD stages 3 to 5: CKD-EPI vs MDRD eGFR

	CKD stage 3-5 classification; % of population			Change in CKD (%) due to CKD-EPI
	MDRD & CKD-EPI	MDRD	CKD-EPI	
All (17,055)	23.4%	25.8%	23.9%	324 (1.9%) ↓
<65 years (9,210)	8.3%	11.5%	8.3%	295 (3.2%) ↓
≥65 years (7,845)	41.2%	42.7%	42.3%	31 (0.4%) ↓
≥75 years (4,394)	50.8%	51.1%	53.1%	88 (2.0%) ↑

- CKD-EPI eGFR resulted in 324 less patients classified with CKD
 - 91% were <65 years
- Of the ≥75 year olds, 2% more patients were classified with CKD using CKD-EPI eGFR
 - These 88 patients would not have been classified by MDRD eGFR
- The increase in CKD diagnosis in the ≥75's - ? compounding risks / faster progression

APEX reports

Creatinine 96 umol/L (59 to 104)

Comments :

Please note:from 07/08/2018 Estimated GFR will be calculated using the CKD-EPI formula.

Please refer to MEMO-EXTCHEM05 EPI dated 30/07/2018

Exponent EPI-eGFR $^{-1.209}$

Estimated GFR 67 mL/min/1.73sq.m

Creatinine 265 umol/L (59 to 104)

Comments :

Please note:from 07/08/2018 Estimated GFR will be calculated using the CKD-EPI formula.

Please refer to MEMO-EXTCHEM05 EPI dated 30/07/2018

Exponent EPI-eGFR $^{-1.209}$

Estimated GFR 19 mL/min/1.73sq.m

Comments :

EGFR result biochemically consistent with CKD stage 4.

Changing to CKD-EPI eGFR at S.V.U.H.

1. DRIVERS FOR CHANGE

- Guidelines
 - Increased accuracy in individuals with better renal function
 - Reduces prevalence of CKD (focused workload)
- Renal physicians on board
 - Cumulative report requested (same test code)

2. COMMUNICATION

- Discussed in-house; meetings, emails and internal memo
- Memo sent to users with lab contact details
 - Change over date provided
 - Indicated MDRD eGFR was being replaced and why *i.e.* adoption internationally, improved accuracy

Changing to CKD-EPI eGFR at S.V.U.H.

3. IMPLEMENTATION INTO IT SYSTEM

- Impact on the IT system was minimal
 - Required dialog with CSC/iSOFT
 - Same test code, comments, results autovalidated

4. IMPACT?

- Differences observed by clinicians is equivalent to reporting any analyte using a new assay
- Minimal; no feedback/complaints = seamless success?

5. UNDERSTANDING?

- Assumption made that users understand limitations of creatinine based formulae
- Ideally requires on-going educational effort: strengths versus weaknesses

Acknowledgements

- Prof Pat Twomey (Consultant Chemical Pathologist/Head of Department)
- Marion Davis (Senior Clinical Biochemist)
- Clinical Biochemistry staff at SVUH